IN2015DN00542A - - Google Patents

Info

Publication number
IN2015DN00542A
IN2015DN00542A IN542DEN2015A IN2015DN00542A IN 2015DN00542 A IN2015DN00542 A IN 2015DN00542A IN 542DEN2015 A IN542DEN2015 A IN 542DEN2015A IN 2015DN00542 A IN2015DN00542 A IN 2015DN00542A
Authority
IN
India
Prior art keywords
compositions
disorders
methods
treating
diseases
Prior art date
Application number
Other languages
English (en)
Inventor
Wei Wei Chang
Kenneth Sawyer
Original Assignee
Rhodes Technologies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhodes Technologies filed Critical Rhodes Technologies
Publication of IN2015DN00542A publication Critical patent/IN2015DN00542A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
IN542DEN2015 2012-07-27 2013-07-26 IN2015DN00542A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261676530P 2012-07-27 2012-07-27
US201361756321P 2013-01-24 2013-01-24
PCT/US2013/052264 WO2014018856A1 (en) 2012-07-27 2013-07-26 Compositions and treatment for eye diseases and disorders

Publications (1)

Publication Number Publication Date
IN2015DN00542A true IN2015DN00542A (zh) 2015-06-26

Family

ID=49997851

Family Applications (1)

Application Number Title Priority Date Filing Date
IN542DEN2015 IN2015DN00542A (zh) 2012-07-27 2013-07-26

Country Status (20)

Country Link
US (2) US20150216877A1 (zh)
EP (1) EP2877184B1 (zh)
JP (1) JP6209777B2 (zh)
KR (1) KR102097663B1 (zh)
CN (2) CN104661663A (zh)
AU (1) AU2013295645B2 (zh)
BR (1) BR112015001847A8 (zh)
CA (1) CA2880027C (zh)
DK (1) DK2877184T3 (zh)
ES (1) ES2759781T3 (zh)
HK (1) HK1210968A1 (zh)
HU (1) HUE046963T2 (zh)
IL (1) IL236920B (zh)
IN (1) IN2015DN00542A (zh)
MX (1) MX362185B (zh)
NZ (1) NZ704247A (zh)
PL (1) PL2877184T3 (zh)
PT (1) PT2877184T (zh)
WO (1) WO2014018856A1 (zh)
ZA (1) ZA201500561B (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
HRP20211377T1 (hr) 2011-11-23 2022-01-07 Therapeuticsmd, Inc. Prirodne kombinirane hormonske supstitucijske formulacije i terapije
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CN105188708B (zh) 2013-03-15 2019-06-28 格利亚有限责任公司 颅部的药物递送
WO2015080758A1 (en) * 2013-11-27 2015-06-04 Al-Qahtani Ahmed H Method and composition for the treatment of moderate to severe keratoconjunctivitis sicca
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
ES2851678T3 (es) 2014-07-21 2021-09-08 Glia Llc Método para el tratamiento de deterioro cognitivo o emocional asociado con la radioterapia y quimioterapia con cannabinoides
CA2951284A1 (en) 2014-07-29 2016-02-04 Therapeuticsmd, Inc. Transdermal cream
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
JP2019513709A (ja) 2016-04-01 2019-05-30 セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. ステロイドホルモン薬学的組成物
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
KR101960023B1 (ko) * 2016-12-21 2019-03-20 김보경 이산화탄소 발생 장치
CA3167771A1 (en) * 2020-02-12 2021-08-19 Glia, Llc Progesterone combinations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5102656A (en) 1983-07-29 1992-04-07 The Mennen Company Antiperspirant creams
US4937069A (en) 1985-11-15 1990-06-26 Bristol-Myers Squibb Company Anhydrous semi-solid antiperspirant suspension
US5069897A (en) 1987-10-16 1991-12-03 The Proctor & Gamble Company Antiperspirant creams
US6659985B2 (en) 2002-01-30 2003-12-09 Southern College Of Optometry Method to use transdermal administration of androgens to the adnexa of the eye
US7572780B2 (en) * 2003-01-21 2009-08-11 Dimera, Incorporated Method and kit for reducing the symptoms of peripheral vascular disease
US20080132475A1 (en) * 2006-12-05 2008-06-05 Charles Gerald Connor Treatment for dry eye
CA2702082A1 (en) 2007-10-08 2009-04-16 Fovea Pharmaceuticals Sa Aqueous ophthalmic formulations
US20100016264A1 (en) * 2007-12-05 2010-01-21 Connor Charles G Treatment for dry eye using testosterone and progestagen
CN101757622A (zh) * 2008-11-28 2010-06-30 天津金耀集团有限公司 一种眼部抗炎的药物组合物
MX359879B (es) * 2009-10-02 2018-10-12 Foamix Pharmaceuticals Ltd Composiciones tópicas de tetraciclina.

Also Published As

Publication number Publication date
ES2759781T3 (es) 2020-05-12
HUE046963T2 (hu) 2020-04-28
MX362185B (es) 2019-01-08
BR112015001847A8 (pt) 2021-09-08
PT2877184T (pt) 2019-12-02
US20170189413A1 (en) 2017-07-06
AU2013295645B2 (en) 2017-08-24
WO2014018856A1 (en) 2014-01-30
ZA201500561B (en) 2016-04-28
DK2877184T3 (da) 2019-12-09
NZ704247A (en) 2018-04-27
EP2877184A4 (en) 2016-03-30
EP2877184B1 (en) 2019-09-04
BR112015001847A2 (pt) 2017-07-04
JP2015524434A (ja) 2015-08-24
CA2880027A1 (en) 2014-01-30
EP2877184A1 (en) 2015-06-03
KR102097663B1 (ko) 2020-04-06
AU2013295645A1 (en) 2015-02-05
MX2015001250A (es) 2015-10-22
JP6209777B2 (ja) 2017-10-11
IL236920B (en) 2018-06-28
CN104661663A (zh) 2015-05-27
CN107595857A (zh) 2018-01-19
KR20150038311A (ko) 2015-04-08
US9925201B2 (en) 2018-03-27
US20150216877A1 (en) 2015-08-06
CA2880027C (en) 2021-12-07
PL2877184T3 (pl) 2020-04-30
HK1210968A1 (zh) 2016-05-13

Similar Documents

Publication Publication Date Title
IN2015DN00542A (zh)
AU2018236800B2 (en) DNA-PK inhibitors
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
EP3185876A4 (en) Compositions and methods for treatment of neurological disorders
PH12015500525A1 (en) Formulations of enzalutamide
EP3024497A4 (en) Methods and compositions for treating brain diseases
EP3182977A4 (en) Compositions and methods to treat vision disorders
EP3160493A4 (en) Compositions and methods to regulate renalase in the treatment of diseases and disorders
EP3086809A4 (en) Compositions and methods of treating ocular diseases
MX2015003701A (es) Composiciones para tratamiento.
EP3515444A4 (en) COMPOSITION FOR TREATING EYE DISEASES AND METHOD FOR USE AND PRODUCTION
PH12016500495A1 (en) Compositions for the treatment of hypertension and/or fibrosis
EP3481958A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF RDH12-RELATED DISORDERS AND DISEASES
EP3370709A4 (en) USE OF PROTEASOME INHIBITORS FOR THE TREATMENT OF EYE DISEASES
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
EP3082427A4 (en) Compositions and methods for treatment of glaucoma
EP3265103A4 (en) Compositions and methods for treating ocular diseases
ZA201408060B (en) Compositions and methods for the treatment of neurological disorders
ZA201408061B (en) Compositions and methods for the treatment of neurological disorders
EP3402511A4 (en) COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES
EP2569018A4 (en) HUMANIZED TTC AND METHOD FOR ITS USE
EP3003341A4 (en) Compositions and methods for treatment of retinal degenerative diseases
EP2999464A4 (en) Methods and compositions for the disruption of biofilms and treatment of disorders characterized by the presence of biofilms
AU2016349439A8 (en) Non-bioconvertible C3-substituted pregnenolone derivatives for use in the treatment of substance use disorders
EP3129054A4 (en) Methods and compositions for the treatment of ocular diseases and disorders